MarketCap
Facebook
X
Telegram
Johnson & Johnson ROA Ratio | JNJ
Annual ROA Ratio Johnson & Johnson
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.46 | 7.81 | 20.98 | 2.45 | 8.41 | - | 9.59 | 10.0 | 11.71 | 11.55 | - | 12.45 | 10.42 | 8.51 | 12.96 | 3.61 | - | 15.25 | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 20.98 | 2.45 | 10.61 |
Quarterly ROA Ratio Johnson & Johnson
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q4 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q4 | 2009-Q3 | 2009-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.62 | 10.89 | 13.82 | 11.21 | 12.73 | 12.64 | 11.67 | 5.99 | 8.74 | 22.9 | 23.0 | 21.07 | 20.87 | 8.08 | 7.44 | 7.48 | 11.04 | 8.49 | 12.08 | 9.2 | 11.28 | 11.52 | 11.7 | 8.11 | 10.65 | 9.68 | 10.95 | 9.59 | 9.03 | 10.49 | 9.52 | 10.0 | 1.2 | 1.02 | 0.87 | 0.83 | 10.05 | 10.7 | 11.12 | 11.58 | 11.69 | 12.07 | 12.57 | 9.3 | 11.23 | 12.34 | 12.21 | 12.46 | 13.18 | 11.8 | 11.39 | 10.42 | 9.89 | 10.09 | 8.36 | 8.94 | 8.72 | 9.13 | 10.45 | 10.44 | 12.68 | 13.3 | 14.56 | 16.19 | 15.71 | 15.9 | 4.84 | - | 3.65 | 3.67 |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 23.0 | 0.83 | 10.68 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Revolution Medicines
RVMD
|
-48.04 | $ 192.41 | 8.31 % | $ 36.6 B |  USA |
 |
Infinity Pharmaceuticals
INFI
|
-105.26 | - | -46.98 % | $ 3.57 M | USA |
 |
OncoSec Medical Incorporated
ONCS
|
-156.23 | - | 31.87 % | $ 1.61 M | USA |
 |
Monopar Therapeutics
MNPR
|
-9.75 | $ 71.6 | 6.52 % | $ 531 M | USA |
 |
Intellia Therapeutics
NTLA
|
-49.01 | $ 11.32 | 1.94 % | $ 1.23 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M |  Israel |
 |
Evelo Biosciences
EVLO
|
-177.72 | - | -14.46 % | $ 27.9 M | USA |
 |
BioDelivery Sciences International
BDSI
|
26.14 | - | -4.8 % | $ 255 M | USA |
 |
Morphic Holding
MORF
|
-21.05 | - | - | $ 2.42 B | USA |
 |
Novan
NOVN
|
-34.66 | - | -24.84 % | $ 2.64 M | USA |
 |
Genocea Biosciences
GNCA
|
-59.31 | - | -15.0 % | $ 3.04 M | USA |
 |
Eiger BioPharmaceuticals
EIGR
|
-193.07 | - | -9.21 % | $ 2.55 M | USA |
 |
Albireo Pharma
ALBO
|
-11.27 | - | -0.23 % | $ 916 M | USA |
 |
BELLUS Health
BLU
|
-18.66 | - | - | $ 2.47 B |  Canada |
 |
bluebird bio
BLUE
|
-52.3 | - | - | $ 546 M | USA |
 |
Intra-Cellular Therapies
ITCI
|
-1.24 | - | - | $ 13.6 B | USA |
 |
IGM Biosciences
IGMS
|
-73.69 | - | - | $ 76.9 M | USA |
 |
Marinus Pharmaceuticals
MRNS
|
-82.74 | - | - | $ 29.6 M | USA |
 |
Merrimack Pharmaceuticals
MACK
|
-6.15 | - | - | $ 216 M | USA |
 |
CASI Pharmaceuticals
CASI
|
-42.62 | - | - | $ 35.4 M | USA |
 |
ContraFect Corporation
CFRX
|
-315.07 | - | -5.16 % | $ 5.39 M | USA |
 |
Sigilon Therapeutics
SGTX
|
-49.91 | - | - | $ 728 M | USA |
 |
Rubius Therapeutics
RUBY
|
-778.79 | - | -33.55 % | $ 7.81 M | USA |
 |
Aptinyx
APTX
|
-97.25 | - | -39.0 % | $ 4.57 M | USA |
 |
TRACON Pharmaceuticals
TCON
|
-35.51 | - | -1.38 % | $ 46.8 M | USA |
 |
Mirati Therapeutics
MRTX
|
-61.6 | - | - | $ 3.3 B | USA |
 |
Revance Therapeutics
RVNC
|
-67.72 | - | - | $ 309 M | USA |
 |
Allogene Therapeutics
ALLO
|
-45.9 | $ 1.03 | -5.5 % | $ 227 M | USA |
 |
InVivo Therapeutics Holdings Corp.
NVIV
|
-55.73 | - | -37.48 % | $ 476 K | USA |
 |
Epizyme
EPZM
|
-86.89 | - | - | $ 249 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-104.83 | - | -9.72 % | $ 5.89 M | USA |
 |
ORIC Pharmaceuticals
ORIC
|
-31.66 | $ 8.87 | 4.48 % | $ 779 M | USA |
 |
Forward Pharma A/S
FWP
|
-2.65 | - | -0.75 % | $ 18.7 M |  Danmark |
 |
Orchard Therapeutics plc
ORTX
|
-68.82 | - | 1.02 % | $ 90.8 M |  Britain |
 |
La Jolla Pharmaceutical Company
LJPC
|
19.42 | - | - | $ 154 M | USA |
|
Oyster Point Pharma
OYST
|
-45.22 | - | - | $ 300 M | USA |
 |
Nabriva Therapeutics plc
NBRV
|
-180.03 | - | - | $ 4.55 M |  Irlanda |
 |
Intercept Pharmaceuticals
ICPT
|
-3.76 | - | - | $ 643 M | USA |
 |
NGM Biopharmaceuticals
NGM
|
-84.31 | - | - | $ 127 M | USA |
 |
Regulus Therapeutics
RGLS
|
-55.07 | - | - | $ 155 M | USA |
 |
9 Meters Biopharma
NMTR
|
-132.03 | - | -42.97 % | $ 1.05 M | USA |
 |
Chinook Therapeutics
KDNY
|
-32.72 | - | - | $ 2.6 B | USA |
 |
Lumos Pharma
LUMO
|
-83.75 | - | - | $ 35.3 M | USA |
 |
Syros Pharmaceuticals
SYRS
|
-97.86 | - | -8.44 % | $ 3.4 M | USA |
 |
NanoViricides
NNVC
|
-83.24 | $ 1.32 | 2.33 % | $ 26.6 M | USA |
 |
Gamida Cell Ltd.
GMDA
|
-46.76 | - | -18.25 % | $ 5.04 M | Israel |
 |
GT Biopharma
GTBP
|
-349.79 | $ 4.42 | -2.64 % | $ 24.4 M | USA |
 |
Aravive
ARAV
|
-122.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
-249.92 | - | -74.18 % | $ 955 K | USA |
 |
Omeros Corporation
OMER
|
-1.03 | $ 16.91 | -1.11 % | $ 1.07 B | USA |